Biography

Guillem is responsible for making and managing investments at Ysios Capital and responsible for reporting to investors.

Guillem has 15 years of venture capital experience. Prior to joining Ysios, he worked at the Edmond de Rothschild Group in Paris (now Andera Partners). There he was involved in the execution of several investments in Europe and the United States, including successful companies such as Reviral (Acquired by Pfizer), Axonics Modulation (Acquired by Boston Sicentific),  Sanifit (Acquired by Vifor) and Verona Pharma (NASDAQ: VRNA).

Guillem is a CFA charterholder. He also holds Bachelor’s degrees in Biotechnology from the Universitat Autonoma de Barcelona, and in Business Administration from the Universitat Pompeu Fabra.

Board positions

Guillem currently serves on the Board of VarmX and Board Observer at Engrail Therapeutics.